

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 Rev. 10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/543,022
Filing Date	September 14, 2006
First Named Inventor	Niva SHAPIRA et al
Group Art Unit	1611
Examiner Name	LANDAU, SHARMILA GOLLAMUDI
Attorney Docket Number	32467

Sheet	2	Of	3
-------	---	----	---

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/A.B./	6	Ahn et al. "Efficacy of Use of Colonoscopy in Dextran Sulfate Sodium Induced Ulcerative Colitis in Rats: The Evaluation of the Effects of Antioxidant by Colonoscopy", International Journal of Colorectal Diseases, 16(3): 174-181, 2001. Abstract.	
/A.B./	7	Cheong et al. "[Suppressive Effects of Antioxidants DA-9601 on Hepatic Fibrosis in Rats]", Taehan Kan Hakhoe Chi, 8(4): 436-447, 2002. Abstract. Article in Korean.	
/A.B./	8	Fitzgerald "Beyond Acid Suppressants in Gastro-Oesophageal Reflux Disease", Gut, 49: 319-321, 2001.	
/A.B./	9	Hahm et al. "Induction of Apoptosis With An Extract of Artemisia Asiatica Attenuates the Severity of Cerulein-Induced Pancreatitis in Rats", Pancreas, 17(2): 153-157, 1998. Abstract.	
/A.B./	10	Huh et al. "Inhibitory Effects of DA-9601 on Ethanol-Induced Gastrohemorrhagic Lesions and Gastric Xanthine Oxidase Activity in Rats", Journal of Ethnopharmacology, 88(2-3): 269-273, 2003. Abstract.	
/A.B./	11	Ji et al. "Metabolism of Eupatilin in Rats Using Liquid Chromatography/Electrospray Mass Spectrometry", Biomedical Chromatography, 18(3): 173-177, 2004. Abstract.	
/A.B./	12	Kim et al. "Combined Use of Omeprazole and A Novel Antioxidative Cytoprotectant for the Treatment of Peptic Ulcer. Facilitation of Ulcer Healing in Experimental Animals", Arzneimittelforschung, 55(7): 387-393, 2005. Abstract.	
/A.B./	13	Lee et al. "Involvement of Oxidative Stress in Experimentally Induced Reflux Esophagitis and Barrett's Esophagus: Clue for the Chemoprevention of Esophageal Carcinoma by Antioxidants", Mutation Research, 480-481: 189-200, 2001. Abstract.	
/A.B./	14	Oh et al. "Oxidative Damages Are Critical in Pathogenesis of Reflux Esophagitis: Implication of Antioxidants in Its Treatment", Free Radic. Biol. Med., 30(8): 905-915, 2001. Abstract.	
/A.B./	15	Oh et al. "Oxidative Stress Is More Important Than Acid in the Pathogenesis of Reflux Oesophagitis in Rats", Gut, 49(3): 364-371, 2001. Abstract.	
/A.B./	16	Ryu et al. "Studies on Protective Effect of DA-9601, Artemisia Asiatica Extract, on Acetaminophen- and CCl4-Induced Liver Damage in Rats", Arch. Pharmacological Research, 21(5): 508-513, 1998. Abstract.	
Examiner Signature	/Audrea Buckley/	Date Considered	01/28/2010

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁷ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

